CTS On The Rebound?
In the battle for the minimally-invasive cardiac surgery market, CTS has long been seen as second fiddle to HeartPort. But while HeartPort has struggled, CTS has been growing nicely. With nearly 50% of the minimally-invasive cardiac surgery market, CTS is now the market leader and watching competitors fall by the wayside. Now the trick is convincing investors.
You may also be interested in...
The predicted expansion of beating-heart and minimally-invasive cardiac surgery never materialized, a result, some say, of the lack of safe and effective automated anastomotic tools. Cardica believes it has the answer that can at long last grow this market.
Gerolymatos International's Sinomarin seawater-based nasal spray is now distributed in France by Laboratoire Gifrer.
New data seems to indicate an uptick in the percentage of premarket applications that receive a major deficiency letter. See what US FDA spokesperson Alison Hunt said about strategies to avoid them.